Latest Racura Oncology (ASX:RAC) News

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.

Racura Oncology has launched patient enrolment at its first Korean site for the CPACS Phase 1 trial, aiming to accelerate recruitment and validate RC220’s safety and efficacy in a key oncology market.

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.

Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.

Small caps drove the week, with battery, resources and education names posting the biggest gains. Deal news, funding rounds and fresh drilling plans kept traders busy, while a few discounted raisings hit hard.

Healthcare stocks split into two camps this week: names with fresh data or contracts found buyers, while capital raisings and trial shock sent others sharply lower. The biggest move came from Cynata’s return to trade, but steady progress in Alzheimer’s, oncology, diagnostics and aged care software also kept the sector busy.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.